Home/Pipeline/OMN-003

OMN-003

Lysosomal acid lipase deficiency

PreclinicalActive

Key Facts

Indication

Lysosomal acid lipase deficiency

Phase

Preclinical

Status

Active

Company

Omnes Therapeutics

About Omnes Therapeutics

A Belgian AAV‑based gene‑therapy platform targeting rare metabolic diseases.

View full company profile

Therapeutic Areas